Intellipharmaceutics International Inc. reported earnings results for the second quarter and six months ended May 31, 2023. For the second quarter, the company reported revenue was USD 0.480203 million. Net loss was USD 0.054121 million compared to USD 0.840654 million a year ago. Basic loss per share from continuing operations was USD 0.002 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.002 compared to USD 0.03 a year ago.
For the six months, revenue was USD 0.806546 million compared to USD 0.016978 million a year ago. Net loss was USD 0.409859 million compared to USD 1.72 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.05 a year ago.